As the United States continues making sweeping revisions to its vaccination recommendations, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who first made her name by questioning Covid vaccinations throughout the pandemic and has concentrated on potential fatalities after COVID-19 immunization in her recent position at the FDA.
Planned Shifts to Pediatric Vaccine Program
Health officials planned to unveil radical changes to the pediatric immunization program in December, synchronizing the US with Denmark’s immunization schedule, according to reports – a major change that would place the US out of alignment with much of the world with little proof for improved outcomes. This reveal has been pushed back until the coming year.
Rather than Vinay Prasad, Dr. Høeg is set to present at the event. She was just designated acting director of the FDA’s CDER, the fifth individual to lead the office this calendar year.
A Shift at the Regulatory Body
This interim role could signify a tighter collaboration between the pharmaceutical and biologics branches as Høeg and Prasad consolidate power at the FDA – and it suggests a increased emphasis upon dismantling already-approved vaccines at the FDA.
The new acting director has frequently advocated for halting specific childhood vaccine recommendations in the US so as to align more like the Danish model, a country with comprehensive healthcare and a number of inhabitants approximately the population of Wisconsin’s.
In her initial comments, she has kept her attention on vaccines – typically the purview of Dr. Prasad, head of the FDA’s vaccine center – rather than drug regulation.
Concerns Over Qualifications
Dr. Høeg has no obvious track record in drug development, approval processes or management, which has been typical for past heads of the CBER. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since spring.
“She doesn’t seem to have any of the qualifications” for running the CDER, said Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in running a sizeable institution. She has no expertise in pharmaceutical oversight.”
Previous commissioners of the center would “understand laws and regulations and the underlying principles of drug development”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that previous people who headed the center have had.”
This division has an vast portfolio at the agency, she stated.
“Everybody just zeroes in on the innovative therapies, but the off-patent medication office approves a multitude of off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and more, and every single one need to be looked after,” Dr. Woodcock noted. “The area you neglect, that’s the thing that I always told people is going to bite you.”
Additionally, a significant leadership aspect to the position, which manages in excess of 5,000 personnel. “It is a massive administrative position, if you do it right,” she concluded.
Response and Controversial Initiatives
When asked about concerns about Dr. Høeg's qualifications and whether this appointment represents more teamwork among agency officials on immunizations, a press secretary stated that the “questions stem from incorrect assumptions”.
“Her experience is consistent with the responsibilities of her position,” the representative said, citing the time Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.
As the temporary head, Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a controversial expedited medication authorization process that reportedly troubled her predecessors. “How are these medications being selected for this fast-track system? Who is making the calls?” Dr. Howard asked. “There’s a lot of secrecy happening at the regulatory body right now.”
Overall, he stated, “the Food and Drug Administration seems to be moving towards more relaxed rules of all drugs, with the exception of immunizations.”
Established Track Record on Immunizations
Concerning immunizations, Høeg has a more established, if concerning, past, critics have noted. She authored a study using unverified public submissions to determine the frequency of myocarditis following COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to indicate Covid vaccinations are riskier than they are.
Among her “wish list” for the new federal leadership featured altering guidelines for new vaccines and discontinuing “unnecessary” immunizations, she stated post-election on a podcast. At the agency, Dr. Høeg has reportedly floated the idea of preventing young men from receiving COVID-19 vaccinations.
“She is an all-around ideologue who begins with her preconceived notions and reverse-engineers to accommodate the evidence in a extremely disingenuous, untruthful manner,” Dr. Howard stated.
Gaining Influence and a “Campaign of Retribution”
Høeg became part of other contrarians, {like|